Imiquimod-induced pruritus in female wild-type and knockin Wistar rats: underscoring behavioral scratching in a rat model for antipruritic treatments.
Imiquimod
Pruritus
Psoriasis
Scratching bout
Wistar rat
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
25 Nov 2023
25 Nov 2023
Historique:
received:
26
05
2023
accepted:
16
11
2023
medline:
27
11
2023
pubmed:
26
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Animal models of skin disease are used to evaluate therapeutics to alleviate disease. One common clinical dermatological complaint is pruritus (itch), but there is a lack of standardization in the characterization of pre-clinical models and scratching behavior, a key itch endpoint, is often neglected. One such model is the widely used imiquimod (IMQ) mouse model of psoriasis. However, it lacks characterized behavioral attributes like scratching, nor has widely expanded to other species like rats. Given these important attributes, this study was designed to broaden the characterization beyond the expected IMQ-induced psoriasis-like skin inflammatory skin changes and to validate the role of a potential therapeutic agent for pruritus in our genetic rat model. The study included female Wistar rats and genetically modified knockin (humanized proteinase-activated receptor 2 (F2RL1) female rats, with the widely used C57BL/6 J mice as a methodology control for typical IMQ dosing. We demonstrate that the IMQ model can be reproduced in rats, including their genetically modified derivatives, and how scratching can be used as a key behavioral endpoint. We systemically delivered an anti-PAR2 antibody (P24E1102) which reversed scratching bouts-validating this behavioral methodology and have shown its feasibility and value in identifying effective antipruritic drugs.
Identifiants
pubmed: 38007440
doi: 10.1186/s13104-023-06627-1
pii: 10.1186/s13104-023-06627-1
pmc: PMC10675923
doi:
Substances chimiques
Antipruritics
0
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
348Informations de copyright
© 2023. The Author(s).
Références
Neuron. 2021 Oct 6;109(19):3075-3087.e2
pubmed: 34411514
Pain. 2016 Nov;157(11):2536-2543
pubmed: 27437787
J Invest Dermatol. 2017 Mar;137(3):546-549
pubmed: 27955901
Front Immunol. 2022 Jun 13;13:728455
pubmed: 35769463
Oncotarget. 2017 Nov 01;9(1):1266-1278
pubmed: 29416693
Nat Methods. 2010 Jun;7(6):447-9
pubmed: 20453868
Sci Rep. 2019 Mar 6;9(1):3685
pubmed: 30842501
Genome Med. 2017 Mar 9;9(1):24
pubmed: 28279190
PLoS One. 2011 Apr 04;6(4):e18266
pubmed: 21483750
Front Med (Lausanne). 2021 Mar 15;8:643006
pubmed: 33791328
Front Mol Neurosci. 2017 Sep 06;10:284
pubmed: 28932184
BMC Res Notes. 2020 Sep 5;13(1):416
pubmed: 32891181
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832
J Invest Dermatol. 1998 May;110(5):734-9
pubmed: 9579537
J Clin Aesthet Dermatol. 2009 Jul;2(7):30-6
pubmed: 20729968
J Allergy Clin Immunol. 2021 Feb;147(2):439-455
pubmed: 32560971
Indian J Pharmacol. 2021 Mar-Apr;53(2):125-131
pubmed: 34100396
J Neurosci. 2008 Dec 17;28(51):13727-37
pubmed: 19091963
Comp Med. 2019 Dec 1;69(6):451-467
pubmed: 31896391
BMC Bioinformatics. 2006 Mar 09;7:123
pubmed: 16526949
Pharmaceutics. 2020 Aug 20;12(9):
pubmed: 32825447
J Invest Dermatol. 2020 Aug;140(8):1524-1532
pubmed: 32004565
Nat Commun. 2013;4:1560
pubmed: 23463003
Mol Biol Rep. 2021 May;48(5):4295-4303
pubmed: 34097205
J Invest Dermatol. 2007 Jun;127(6):1292-308
pubmed: 17429444
Dermatol Ther (Heidelb). 2019 Sep;9(3):407-420
pubmed: 31256388
Anat Rec (Hoboken). 2018 Jan;301(1):166-174
pubmed: 28926201